Top-Rated StocksTop-RatedNASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis $81.61 +1.66 (+2.08%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$81.23▼$83.1750-Day Range$65.62▼$84.0152-Week Range$39.86▼$89.39Volume160,942 shsAverage Volume415,751 shsMarket Capitalization$5.27 billionP/E RatioN/ADividend YieldN/APrice Target$96.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nuvalent alerts: Email Address Nuvalent MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside18.0% Upside$96.33 Price TargetShort InterestBearish22.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 8 Articles This WeekInsider TradingSelling Shares$8.34 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.06) to ($3.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.64 out of 5 starsMedical Sector877th out of 936 stocksPharmaceutical Preparations Industry413th out of 436 stocks 2.5 Analyst's Opinion Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNuvalent has only been the subject of 2 research reports in the past 90 days.Read more about Nuvalent's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.39% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 19.3, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently increased by 3.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVL. Previous Next 2.0 News and Social Media Coverage News SentimentNuvalent has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nuvalent this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,344,660.00 in company stock.Percentage Held by Insiders12.52% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvalent's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($3.06) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -33.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -33.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 7.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvalent's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Nuvalent Stock (NASDAQ:NUVL)Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More NUVL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVL Stock News HeadlinesJuly 18, 2024 | insidertrades.comEmily Conley Sells 5,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) StockJuly 17, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Director Sells $403,600.00 in StockJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.July 11, 2024 | insidertrades.comDeborah Ann Miller Sells 3,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) StockJuly 3, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Insider Sells $377,700.00 in StockJune 27, 2024 | insidertrades.comMatthew Shair Sells 2,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) StockJuly 25 at 2:10 AM | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 24 at 4:13 AM | americanbankingnews.comNuvalent (NASDAQ:NUVL) Stock Rating Reaffirmed by WedbushJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.July 22, 2024 | prnewswire.comNuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective InhibitorJuly 22, 2024 | prnewswire.comNuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective InhibitorJuly 17, 2024 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Insider Deborah Ann Miller Sells 6,000 SharesJuly 16, 2024 | prnewswire.comNuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024July 11, 2024 | prnewswire.comNuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific OfficerJune 24, 2024 | seekingalpha.comNuvalent: Making Precise Progress In Its Oncology PipelineJune 24, 2024 | investorplace.com3 Short-Squeeze Stocks Poised for a Jaw-Dropping RallyJune 14, 2024 | seekingalpha.comNuvalent: NVL-655 Could Bring Blockbuster PotentialMay 29, 2024 | prnewswire.comNuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceSee More Headlines Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NUVL CUSIPN/A CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$96.33 High Stock Price Target$115.00 Low Stock Price Target$42.00 Potential Upside/Downside+18.0%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.54% Return on Assets-25.22% Debt Debt-to-Equity RatioN/A Current Ratio20.93 Quick Ratio20.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book7.46Miscellaneous Outstanding Shares64,556,000Free Float56,474,000Market Cap$5.27 billion OptionableOptionable Beta1.28 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. James R. Porter Ph.D. (Age 48)CEO, President & Director Comp: $1.05MProf. Matthew D. Shair Ph.D. (Age 55)Founder, Head of Scientific Advisory Board & Director Comp: $239kMs. Alexandra Balcom CPA (Age 39)M.B.A., CFO & Treasurer Comp: $689.41kDr. Christopher D. Turner M.D. (Age 55)Chief Medical Officer Comp: $750.97kDr. Benjamin Lane Ph.D.Senior Vice President of Technical OperationsMs. Deborah Ann Miller J.D. (Age 48)Ph.D., Chief Legal Officer & Secretary Comp: $595.96kMr. Matthew MetivierSenior Vice President of Human ResourcesMs. Darlene Noci (Age 46)Chief Development Officer Mr. Henry Pelish Ph.D.Senior Vice President of Drug DiscoveryMr. John Soglia Ph.D.Senior Vice President of Translational DevelopmentMore ExecutivesKey CompetitorsChinook TherapeuticsNASDAQ:KDNYPraxis Precision MedicinesNASDAQ:PRAXIGM BiosciencesNASDAQ:IGMSOcugenNASDAQ:OCGNGossamer BioNASDAQ:GOSSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 25,966 shares on 7/26/2024Ownership: 0.214%China Universal Asset Management Co. Ltd.Sold 4,317 shares on 7/20/2024Ownership: 0.011%Emily ConleySold 5,000 sharesTotal: $403,600.00 ($80.72/share)Deborah Ann MillerSold 6,000 sharesTotal: $480,960.00 ($80.16/share)SG Americas Securities LLCBought 1,745 shares on 7/12/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions NUVL Stock Analysis - Frequently Asked Questions How have NUVL shares performed this year? Nuvalent's stock was trading at $73.59 on January 1st, 2024. Since then, NUVL shares have increased by 10.9% and is now trading at $81.61. View the best growth stocks for 2024 here. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.02. When did Nuvalent IPO? Nuvalent (NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's top institutional investors include Bank of New York Mellon Corp (0.21%), Renaissance Capital LLC (0.04%), Harbor Capital Advisors Inc. (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Matthew Shair, Alexandra Balcom, Darlene Noci, Deborah Ann Miller, Christopher Durant Turner and Emily Conley. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NUVL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.